In addition, a recent meta-analysis indicated that TKIs treating NSCLC with ALK/ROS1 rearrangements did not significantly increase the VTE risk compared with platinum-based chemotherapy by analyzing 6 randomized control studies (44). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.